/MGTX
MGTX Stock - MeiraGTx Holdings plc
Healthcare|BiotechnologyNASDAQ
$8.03+0.88%
+$0.07 (+0.88%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.57
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.64
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+124.2%upside
Target: $18.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MGTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.95 – $8.11
TARGET (TP)$18.00
STOP LOSS$7.39
RISK/REWARD1:15.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.39
52W High$9.73
52W Low$4.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $33.28M | $14.02M | $15.92M | $37.70M | $15.56M |
| Gross Profit | $9.49M | $14.02M | $15.92M | $37.70M | $15.56M |
| Gross Margin | 28.5% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-164,212,000 | $-137,061,000 | $-116,355,000 | $-72,758,000 | $-62,554,000 |
| Net Income | $-147,791,000 | $-84,027,000 | $-129,615,000 | $-79,561,000 | $-57,992,000 |
| Net Margin | -444.1% | -599.5% | -814.2% | -211.0% | -372.6% |
| EPS | $-2.12 | $-1.49 | $-3.16 | $-1.63 | $-1.43 |
Company Overview
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
1
33%
Buy / Outperform
2
67%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$28
Average Target
↑ 252.8% Upside
Now
$20
Low
$28
Average
$36
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | H.C. Wainwright | Initiation | Buy | $20 |
| October 21st 2025 | Raymond James | Initiation | Strong Buy | $29 |
| July 31st 2024 | Chardan Capital Markets | Resumed | Buy | $36 |
Earnings History & Surprises
MGTXBeat Rate
28%
Last 18 quarters
Avg Surprise
-36.9%
EPS vs Estimate
Beats / Misses
5/13
Last 12 quarters
Latest EPS
$-0.62
Q4 2025
EPS Surprise History
Q1 24
-2.2%
$-0.47vs$-0.46
Q2 24
-140.6%
$-0.77vs$-0.32
Q3 24
-145.2%
$-0.76vs$-0.31
Q4 24
-14.9%
$-0.54vs$-0.47
Q1 25
-4.2%
$-0.50vs$-0.48
Q2 25
-34.2%
$-0.51vs$-0.38
Q3 25
+7.7%
$-0.48vs$-0.52
Q4 25
-24.0%
$-0.62vs$-0.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.60 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.50 | $-0.62 | -24.0% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.52 | $-0.48 | +7.7% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.38 | $-0.51 | -34.2% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.48 | $-0.50 | -4.2% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.47 | $-0.54 | -14.9% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.31 | $-0.76 | -145.2% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.32 | $-0.77 | -140.6% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.46 | $-0.47 | -2.2% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.63 | $-0.74 | -17.5% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.59 | $-0.53 | +10.2% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.65 | $-0.62 | +4.6% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $0.49 | $-0.58 | -218.4% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.50 | $-0.83 | -66.0% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.58 | $-0.76 | -31.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.49 | $-0.70 | -42.9% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.49 | $-0.22 | +55.1% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.52 | $-0.59 | -13.5% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.53 | $-0.46 | +13.2% | ✓ BEAT |
Latest News
HC Wainwright & Co. Initiates Coverage On MeiraGTx Hldgs with Buy Rating, Announces Price Target of $20
📈 PositiveBenzinga•Nov 24, 2025, 03:14 PM
RBC Capital Maintains Outperform on MeiraGTx Hldgs, Raises Price Target to $16
📈 PositiveBenzinga•Nov 14, 2025, 03:53 PM
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $35 Price Target
📈 PositiveBenzinga•Nov 14, 2025, 01:25 PM
MeiraGTx Hldgs Q3 EPS $(0.62) Misses $(0.50) Estimate, Sales $410.000K Miss $6.960M Estimate
📉 NegativeBenzinga•Nov 13, 2025, 01:11 PM
Piper Sandler Maintains Overweight on MeiraGTx Hldgs, Raises Price Target to $30
📈 PositiveBenzinga•Nov 11, 2025, 05:22 PM
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $35 Price Target
📈 PositiveBenzinga•Nov 11, 2025, 01:07 PM
Eli Lilly in pact with MeiraGTx to develop gene therapies for eye diseases
📈 PositiveSeeking Alpha•Nov 10, 2025, 12:39 PM•Also:
MeiraGTx Holdings Announced A Broad Strategic Collaboration In The Area Of Ophthalmology With Eli Lilly And Company
📈 PositiveBenzinga•Nov 10, 2025, 12:12 PM•Also:
MeiraGTx Holdings shares are trading higher. Raymond James initiated coverage on the stock with a Strong Buy rating and price target of $29.
📈 PositiveBenzinga•Oct 21, 2025, 06:13 PM
Raymond James Initiates Coverage On MeiraGTx Hldgs with Strong Buy Rating, Announces Price Target of $29
📈 PositiveBenzinga•Oct 21, 2025, 05:40 PM
MeiraGTx Sales Jump 1,133 Percent
📈 PositiveThe Motley Fool•Aug 14, 2025, 12:31 PM
Frequently Asked Questions about MGTX
What is MGTX's current stock price?
MeiraGTx Holdings plc (MGTX) is currently trading at $8.03 per share. The stock has moved +0.88% today.
What is the analyst price target for MGTX?
The average analyst price target for MGTX is $18.00, based on 1 analyst.
What sector is MeiraGTx Holdings plc in?
MeiraGTx Holdings plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MGTX's market cap?
MeiraGTx Holdings plc has a market capitalization of $0.65 billion, making it a small-cap company.
Does MGTX pay dividends?
No, MeiraGTx Holdings plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABSI
Absci Corporation
$3.38
Mkt Cap: $0.5B
ARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
ATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
IOVA
Iovance Biotherapeutics, Inc.
$2.48
Mkt Cap: $0.8B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
Explore stocks similar to MGTX for comparison